Good afternoon. Welcome to Establishment Labs Fourth Quarter 2024 Earnings Call. At this time, all participants will be in a listen only mode. As a reminder, today's call is being recorded. I will now turn the call over to Raj Denhoy, Chief Financial Officer. Please go ahead.

Thank you, operator. And thank you everyone for joining us. With me today is Juan Chacón-Quirós, our Chief Executive Officer; and Peter Caldini, our President. Following our prepared remarks, we'll take your questions. Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meanings of federal securities laws. These include statements on Establishment Labs' financial outlook and the company's plans and timing for product development and sales. These forward-looking statements are based on management's current expectations and involve risks and uncertainties. For a discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage you to review our most recent annual and quarterly reports on Form 10-K and Form 10-Q as well as other SEC filings, which are available on our website at establishmentlabs.com. I'd also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including, but not limited to sales results, which can be stated on a constant currency basis or profitability of the company's business, which can be stated as EBITDA or adjusted EBITDA. Reconciliations to comparable GAAP financial measures for non-GAAP measures, if available, may be found in today's press release, which is available on our website. The content of this conference call contains time sensitive information accurate only as of the date of this live broadcast, February 26, 2025. Except as required by law, Establishment Labs undertakes no obligation to revise or otherwise update any statement to reflect events or circumstances after the date of this call. With that, it is my pleasure to turn the call over to our CEO, Juan Chacón-Quirós.

Thank you, Raj. And good afternoon, everyone. Revenue in the fourth quarter of 2024 totaled $44.5 million in line with our expectations and with what we preannounced in early January. For the full year, our sales were $166 million. We remain committed to our forecast for 2025 guidance between $205 million and $210 million. At its midpoint, this is 25% growth over 2024. With our launch in the United States, the fourth quarter was easily one of the most important in our company's history. US sales totaled $3.3 million in the first two months of the launch, a bit better than we preannounced in early January. This is an incredibly strong start and our US commercial team, one of the strongest teams ever put together in aesthetics, deserves recognition for their efforts. This strong start has continued into Q1 and the activity and interest around Motiva continues to grow. In the fourth quarter, we continue to see the tangible results of the efforts we've undertaken over the past year to reduce our operating expenses and cash use. In 2024, our total operating expenses were $12.5 million lower than in 2023, and this includes our 2024 spend to build the commercial infrastructure for rollout in the United States. EBITDA loss improved to $13.1 million this quarter from $17.4 million last year. Our successful launch in the United States and the gross margin expansion it brings, along with our continued focus on operational efficiency, should take us to our first positive EBITDA quarter in 2025. Outside the United States, global demand remains uneven, but our data suggests that we are picking up market share as all aesthetic companies manage through this period. This low in aesthetic demand has happened before and it has always recovered. Specifically, we believe a number of countries in EMEA were down last year, in some cases meaningfully, and yet our revenue remained flat in that region. Asia Pacific in 2024 has been recovering from the sharp downturn we saw in the second half of 2023. This regional strength was offset by the continued weakness in Latin America. Excluding currency and other external items, revenue in Lat-Am in the fourth quarter of 2024 was flat from the previous year, suggesting that our results are stabilizing in that region. 2025 should mark a gradual return to growth outside the United States. And while we are being conservative as markets and regions return, growth in the mid single digits in these markets looks very achievable. We have also not included any significant contribution from new products or regulatory approvals, which could provide an upside to our numbers. While OUS remains the largest segment for us, most important to our company's future is the United States, and our results continue to exceed our expectations. We have 40 sales reps active in the field. We continue to attract the best and brightest in the industry and we'll expand this theme in 2025. As of last Friday, we have over 650 accounts fully onboarded and 450 have already placed orders with 88% reordering. These are all well ahead of our expectations. We continue to sign up an average of five new accounts every day. Momentum is building. In November, we averaged 32 orders per day. In December, we averaged 60 orders per day. In January, we averaged 70 orders per day. And in February, we should average about 90 orders per day. Since launch, we have had more than 5,000 orders. We expect to generate approximately $5.5 million in sales in the first quarter, putting us on the strong trajectory to exceed our guidance of $35 million in sales in 2025 for the United States. Please remember that breast augmentation is seasonal. Second and fourth quarters are the strongest. First and third are the weakest. We are on pace to have one of the best launches in the history of the aesthetics industry. As we study our initial rollout, we are seeing confirmation that the United States will likely mimic our initial rollout in Switzerland, South Korea and Taiwan, markets that are relatively high priced, smooth implant markets. In Switzerland, we reached 50% market share after five years in the market and 70% market share at year 10. In South Korea, we reached 40% market share after four years in the market and 65% market share in year eight. In Taiwan, our latest launch, we have now reached 40% market share after four years. Beyond the strong financial results, the interest in Motiva among plastic surgeons, the media and most importantly women, has been nothing short of remarkable. We hear a constant refrain from plastic surgeons: when given a choice between Motiva and other implants, patients almost always choose Motiva. This is true even though Motiva implants have a higher blended price point. In these first five months of the launch, we have seen almost without exception that plastic surgeons who convert to Motiva stay with Motiva. And for most of those who started early in our launch, Motiva has become the vast majority of their implant usage. In just a few months, there have been over 60 press articles mentioning Motiva and hundreds of social media posts from surgeons. We have had over 1.8 billion impressions from this activity. Importantly, all of this is happening organically without financial support. I would encourage you to follow the content being created by many plastic surgeons and clinics on Instagram, TikTok and other digital platforms as it speaks to the viral nature of our launch. With the buzz building, we have had a number of celebrities and influencers organically choosing Motiva and I would expect this to continue. With a differentiated value proposition, these women seem more open to discussing their choices and timing. This is unusual in aesthetics. Plastic surgery decisions tend to be kept private. Even more unusual is a discussion around specific brand choices. With this interest, we have been working on a partnership with an A-List celebrity who recently chose Motiva implants and we hope to announce it in the very near future. This should be very impactful, not just in the United States but globally. Women tend to do considerable research around breast augmentation before making a decision and the social media and press coverage should help Motiva spark a conversation between patient and doctor. The partnership should also resonate with plastic surgeons who often feel unsupported by an aesthetic industry focused on other specialties. As we build the premier trusted company for plastic surgeons, these kinds of efforts will make a big difference. In reconstruction, Flora, our unique tissue expander, is gaining traction and we have completed the VAC process at 35 of the premier cancer centers in the United States. 32 have already ordered and the other three were opened in the last 30 days. A recent scientific publication from an interdisciplinary group devoted to treating breast cancer and performing breast reconstructions at the MD Anderson Cancer Center in Texas concluded that the integration of MRI CTEs into radiation therapy planning has streamlined the process, reduced the need for artifact management and improved the accuracy of those calculations, ultimately contributing to better clinical outcomes. As a women's health company, we are pleased to witness the positive impact of our technologies like Flora in the process of treating breast cancer and helping women recover to their fullest after survival. This will be a busy year for the regulatory team in the US as we seek clearance for a number of products. In reconstruction, we are on track to reach a three-year follow-up in the third quarter of this year. This puts us on track to submit to the FDA this year with a potential approval for this indication in 2026. The reconstruction market is nearly as big as augmentation in the US, and we are excited to bring our technologies to this important segment. We are also working on approval for the tools necessary to launch Preservé, including the submissions necessary for the Ergonomix2 platform. The Ergo2 platform will allow for us to bring Mia Femtech to the United States. We will provide some thoughts on the regulatory pathway and timing later in the year. Mia Femtech continues to build a new category in breast aesthetics. It is important to note that we launched Mia in Europe in late 2023. By the end of 2024, in less than 18 months, we already had more than 60 clinics become Mia certified centers. As we see Mia sales ramp, it is becoming clear that a minimally invasive solution which overcomes many of the obstacles of traditional breast augmentation can open up a new group of women to breast aesthetics. We have moved beyond the proof of concept phase and expect to see a steady increase in results from Mia over the coming quarters. For 2025, we expect the number of Mia certified clinics to at least double and that the number of Mia procedures globally will more than double, and we are forecasting approximately $8 million to $10 million in revenue from Mia this year. One of the key learnings from the three-year data from the Mia IRB study and the outcomes we are seeing in the real world has been that preserving breast tissue has advantages beyond the periprocedural benefits of a minimally invasive procedure. By not cutting the breast tissue but rather by preserving it as the Mia tools allow, the results can be much more predictable and stable over time. We pioneered the concept of breast tissue preservation and it resonates with plastic surgeons who already appreciate the reduction of device-related complications with Motiva and now are also seeing a reduction of technique-related complications, thanks to breast tissue preservation. With these fundamental concepts, we have developed Preservé, the next step in our minimally invasive portfolio. Mia's value proposition to patients is clear. It is intended for primary augmentations with a one to two cup size increase and for a scarless lift for women with mild breast ptosis. There are no scars on the breast and an imperceptible scar on the armpit. It is done under local anesthesia. As the Mia IRB study shows, there is no loss of breast sensation, no inferior malposition of the implant and it dramatically reduces patient recovery periods and complications traditionally associated with breast augmentations. It is also priced as our most premium product to reflect these aspects. Mia is designed to appeal to women who are not interested in breast augmentation or are using padded or pushup bras and so by definition should be market expanding. Preservé is designed for the day-to-day procedures that make up the majority of breast augmentation. While Preservé should be market expanding over time given its benefits, it is designed to be the premium choice for women who are already considering breast augmentation surgery. Preservé can be used for up to four cup sizes increase and can be used for primary augmentations, hybrid augmentations and for mastopexy augmentations. Preservé uses some of the surgical tools developed with Mia to make a precise atraumatic pocket but the incision is made under the breast, which is a more familiar surgical technique for most doctors. The technology platform allows plastic surgeons to create natural results by preserving breast anatomy and function. We have been talking about Preservé with the plastic surgery community since last year and they are eager to discuss it with prospective patients. Preservé is a new choice for women considering breast augmentations as it speaks to many of their aspirations, including more natural results, smaller scars and quicker recovery. By improving safety profiles, recovery times and achieving the breast aesthetic patients are looking for, Preservé has the potential to make breast augmentation more appealing to women and make the decision easier for many who are already in the consideration phase. We launched Preservé earlier this month in Brazil and it is clearly resonating. In the first week post-launch, we have seen significant interest and have already received many orders for hundreds of systems at a price point more than double or as most common SKUs in Brazil. We'll continue our rollout into additional countries and regions over the coming quarters. We expect that both breast tissue preservation options, Mia and Preservé, will dramatically change the surgeon's approach to breast aesthetics and have a significant impact on future growth. Preservé will bridge the price gap between existing Motiva offerings and Mia and will be at the upper end of our pricing metrics. Finally, it is worth noting that GLP-1 usage is going to be a major tailwind for years to come. Much of this demand is market expanding. And while we are starting to see it now where GLP-1 adoption is more prevalent, we do expect this to be a global tailwind. Our products and messaging with Mia and Preservé are particularly suited for women who are considering augmentation as a way to reverse some of the atrogenic consequences of GLP-1 weight loss and we expect to do very well in this new market segment. 2024 was an important year for us in China. We established our presence in the market with our exclusive distribution partner and began building the foundation for market share gains. As we have commented previously, the first year of any distributor market will be about selling as the distributor puts inventory into the field and begins commercial sales. We will now see the sellout as our partner grows share in the market. Based on this dynamic, we do not expect to see revenue in the first part of 2025 with reorders beginning more meaningfully in the second half of the year. This is a natural cadence for distributor markets and allows us to maintain a healthy level of inventory in the channel. The ordering pattern is reflected in our guidance for this year. Importantly, our Chinese partner recently signed an agreement with CBC Group for strategic financing of up to $50 million to fund commercial activities in support of the continuous growth of Motiva in China. This investment is being used to increase the number of sales reps across China and add more regional commercial dealers. We have already begun to see the tangible results with end consumer sales in the first part of this year increasing meaningfully from last year. We are very confident that this investment into our partner will help us become the leading technology in China in the next few years and is already the case in the rest of Asia.

Thank you, Juan Chacón-Quirós. This is my first call since joining Establishment Labs, and I am excited to be here at such an exciting time for the company. When I first looked at Establishment Labs, I had some preconceived notions of what the breast augmentation industry could be. However, on my first trip down to Costa Rica, I realized what an amazing company and opportunity existed. Our innovations are radically changing the breast augmentation and reconstruction industries, opening the procedure to many women who would not have considered it previously. Our Motiva implant has FDA data that is remarkably better than any data ever seen in a breast implant trial. These are not small differences, and it creates a huge opportunity to build a best-in-class company and reshape an industry. Managing the growth and opportunity of this scale has its challenges, and that is why I'm very excited to be part of the team. Marrying growth and opportunity with efficiency and productivity is where I can really add value, and with it meet and exceed our cash flow and profitability targets. Over the last year, we have made a number of changes that are positively impacting our financials. We reduced our operating expenses by $12.5 million in 2024 while at the same time standing up a significant commercial operation in the United States. We have rightsized the global organization, eliminating headcount by more than 30% in some areas and streamlined departments to ensure greater alignment and efficiencies. We are focused not only on reducing costs but also improving our overall return on investment. In preparing for the US, we built a world-class sales and marketing organization and have invested meaningfully in building inventory to support our launch. We've been able to fund a good portion of this by reducing corporate costs and enhancing efficiency across the organization. Among the changes we made is closing B15, our first and smallest manufacturing facility. This is in part reflected with the stronger gross margins we see in the fourth quarter. We have also made changes to better align our commercial and marketing organizations. We have reallocated resources to better performing initiatives and implemented better processes to ensure that we deliver on our financial commitments. Recently, we completed the acquisition of our distributor in Benelux. With our long-term partner in the region retiring, we took the opportunity to leverage the infrastructure we already have in place with our European distribution center in Antwerp to achieve meaningful synergies over time. As we look out to 2025, these efforts will continue in earnest. Raj will provide details on our financial targets for the year in a moment. But as a company, we are very focused on being EBITDA positive by the end of the year and cash flow positive next year. Our board and the management team are aggressively focused on these targets, and we will continue to do what's necessary to achieve them. I look forward to reporting on our progress over the coming quarters.

Thank you, Peter. Total revenue for the fourth quarter was $44.5 million, an increase of 41% from the year-ago period. Foreign exchange reduced sales by approximately 2 percentage points in the quarter. From a regional perspective, sales in Europe, Middle East and Africa were approximately 38% of the global total, Asia Pacific 35%, Latin America 18%, and North America was 9%. As noted previously, North American sales included $3.3 million of Motiva sales in the United States. Our gross profit for the fourth quarter was $30.5 million or 68.5% of revenue compared to $20.6 million or 65.2% of revenue for the same period in 2023. The gross profit in the fourth quarter was positively impacted by higher production volumes, the decommissioning of our B15 manufacturing site, and the early contribution of sales in the US. We expect this number to continue to improve as we ramp sales in the United States. SG&A expense for the fourth quarter increased approximately $7.1 million to $44 million. This compared to $36.9 million in the fourth quarter of 2023. The increase is due to the ramp-up of commercial activity in the United States following approval of Motiva implants in late September, as well as the operating expenses in the Benelux subsidiary we acquired in the fourth quarter. R&D expenses for the fourth quarter declined approximately $0.7 million from the same quarter a year ago to $5.1 million. The increase in operating expenses in the fourth quarter was primarily the result of the increased investment in our US operations. These were offset by the cost reduction initiatives we undertook in the second half of 2023 and which continued into 2024. Total operating expenses for the fourth quarter increased approximately $6.4 million from the year-ago period. Net loss from operations for the fourth quarter was $18.7 million compared to a net loss of $22.1 million in the same period in 2023. Adjusted EBITDA was a loss of $13.1 million in the quarter compared to a loss of $17.4 million in the fourth quarter of last year. We've taken tangible steps to reduce spending over the recent quarters as we have reduced our operating loss meaningfully even as we increase spending on the launch of Motiva in the United States. Overall for 2024, operating expenses declined approximately $12.5 million from 2023. Despite our investments in the United States, our EBITDA loss improved significantly to $28.2 million from $47 million in 2023. Our cash position on December 31st was $90.3 million. This compared to $39.7 million at the end of the third quarter. The end of the year balance includes the proceeds from a registered direct offering on November 7th and the proceeds from the tranche of our credit facility that became available on US Motiva approval. We have one additional tranche available in our credit facility for $25 million, bringing our total accessible cash balance to approximately $115 million. Our cash usage before finance in the fourth quarter was $22.6 million. The fourth quarter, as well as the first quarter, will be the highest for us in terms of cash use as we're seeing the investment in the United States commercial efforts as well as the increase in inventory needed to support the strong demand we are seeing for our US launch. Our cash usage will improve meaningfully as the year progresses, and we leverage these investments against higher sales in the United States. As our revenue scales, the business should start generating substantial cash flow, and we believe we will reach cash flow breakeven in 2026. Our initial revenue guidance for 2025 is $205 million to $210 million, representing growth of 23% to 26%. Our expectation remains for our OUS business to grow in the mid single digits on an underlying basis. While foreign currency remains volatile at current exchange rates, we expect revenue outside the United States to be approximately $170 million to $175 million. Currency is expected to negatively impact 2025 reported sales results by approximately $2 million to $3 million. We continue to expect at least $35 million in US revenue in 2025. Gross margins in 2025 should be approximately 200 to 300 basis points higher on an underlying basis. This increase is being driven by the higher selling prices in the US and with our other new product launches. We remain very focused on managing operating expenses. And we expect total operating expenses will be approximately $45 million to $46 million per quarter, including approximately $6 million to $7 million of noncash expenses. This represents a step up in operating expenses for the US, offset by continued efficiencies in our core business. We are on track to be EBITDA positive in the second half of 2025.

Thank you, Raj. As we communicated earlier this year, I am retiring from my position as CEO of Establishment Labs effective March 1st. As the founder of this company more than twenty years ago, it was not an easy decision to step aside but it was the right one. And as one of the largest shareholders of the company, I look forward to our bright future. However, I will continue to be involved with Establishment Labs in the things I love and I am best at, creating value through innovative concepts, overseeing the technology development and interacting with the surgeon community to promote these innovations while telling the amazing story of Establishment Labs. I am not going anywhere. In fact, later this week, we have another delegation of US surgeons coming to Costa Rica, and I will be hosting them at our Sulàyöm innovation center. I will also be at the American Society of Plastic Surgeons meeting in Austin next month, hosting several events with KOLs and many other meetings and events this year. This is an evolution for me into a new role at Establishment Labs. I like to call it the Chief Evangelist. We have accomplished an enormous amount over the past twenty years. We have transformed the breast aesthetics and reconstruction industry and dramatically reduced the rates of device-related complications. We have brought key innovations to market like our proprietary low inflammatory SmoothSilk surface, micro transponder technologies and biosensors like Zen, the first and only ergonomic breast implant, Flora, the first commercial breast tissue expander that allows for MRIs, next-generation super silicones, and now our minimally invasive platform in breast tissue preservation with Mia and Preservé. At the surgical center in Sulàyöm, we are designing and teaching the surgical techniques to simplify the adoption of minimally invasive and breast tissue preservation. We have scaled our manufacturing to where we can produce over 1 million implants a year. We have established sales and distribution in over 90 countries. The track record of less than 1% device-related complications with the over 4 million devices we have sold has had an enormous impact on the lives of women in every corner of the globe, including the US and China. The next level for us as a company, however, is to build on this foundation of innovation in an efficient and profitable way. And so I decided to create space to bring someone in with deep experience scaling companies globally to profitability. While the board is doing a market check, I think Peter Caldini will do a wonderful job as interim CEO and could certainly handle the role on a permanent basis as well. I will now turn the call over to the operator for your questions.

Our first question is from Anthony Petrone with Mizuho Group.

And first JJ, good luck into the transition and obviously, congratulations on building a great organization and Pete, good luck as interim and through the transitional process. Maybe first to go into the dynamics on the US Motiva launch, couple questions there and I'll have a quick follow up. Maybe just an update on how many accounts you're in? I think the number exiting last year was around 500. JJ you gave some good color on ordering patterns here. Through February, I'm just wondering how that matches up in terms of total live accounts in the US? And then when you think about the $35 million guide, wondering if FDA clearance of Ergonomix2 is baked into that number? And I'll have one quick follow up.

Yes, we're beyond happy with what we are seeing in the market with the US launch. And some of the color that we gave today is particularly important, because we have 650 accounts that have been fully onboarded and out of those 450 have already placed orders and almost 90% of them have been reordering. And when you look at those that have not ordered yet, those are accounts that we are recently onboarded. So if you add to that, that we are signing up an average of five accounts per day, it gives you how this is going to scale up over the next few quarters. Remember, accounts that begin with Motiva doesn't mean they'll start using Motiva on day one. It means they'll start offering Motiva to their patients in their consultations after that. So they may be booking surgeries that are weeks away or sometimes months away. And the important thing for us at this point is to be focusing on the two things that matter, continuing to add new accounts but now it also shifts the focus as well to the reordering patterns. And when we look at some of our largest accounts to date, their reordering patterns is exactly what we want to see. On your other question, our $35 million does not include any new approval in the United States.

And the quick follow-up would just be maybe a recap on the macro front around the world. It sounds like we're still not quite out of the woods in terms of aesthetics, but there are some signs of green shoots. So maybe just the backdrop on aesthetics, key regions, US, China and Brazil? Thanks again.

Yes, I think it's important to realize that there's still microeconomic pressures. But when we think about Latin America, where we're not expecting growth from Latin America this year, we are also seeing very good signs that the situation is no longer deteriorating in Latin America. We already saw that in Q4. And as we look into EMEA and APAC, that's where the growth will come from. But we've guided, I think, in a very conservative way to about mid single digits. And that does not take into account any potential contributions from new regulatory approvals or launches like Preservé. So I think we're in a good place for a year of growth. And even though there will be macro pressures in different areas, I think we have enough evidence to feel that what we've said is totally achievable.

Our next question is from Allen Gong with JPMorgan.

Just to start off with one on the US launch. It definitely seems as though you've got good momentum and you provided really good color on kind of the order rate on a daily basis. But just doing some napkin math and fully understanding that it's not quite that straightforward to get to actual revenues, but it looks as though your momentum so far in January and February already implies that the $5 million in first quarter looks like it could be really, really conservative given that just the average daily orders you've seen so far. So why was $5 million the right target to start off the year and kind of what are you assuming in March?

For us, it's still early in the launch, right? So we had approval late September, as you know, we launched in October. Things are going exceedingly well as Juan already described with the order numbers that we're seeing and how it's ramping. We'd agree with you, right, that the numbers we've given could look conservative, but it's still early in the launch. So we want to give ourselves some room. And again, so far everything is tracking, but we want to give ourselves a little bit of time to see how things develop.

And then when we think about kind of the trajectory of your operating expense, right, you provided the kind of quarterly value that you're kind of expecting it to fall into. But when we think about the fact that some of the big step up sequentially from third quarter into fourth quarter is to sort of stand up the US launch, you've reached that 40 rep target that you've kind of been talking about. How should we think about the trajectory of SG&A going forward given some of that spend should be one time in nature and arguably can come out of the model in maybe the back half of the year?

Well, I don't think you should look at it as one-time in nature, right? So we have hired sales people, we've established the US commercial operation, and that infrastructure is now in place, right? And as you move through the year, the leverage you'll see in the model is as we leverage that. And so the necessity to add on top of that will be opportunistic on our part and we're seeing really strong demand in the US. And so we could add more sales people as the year goes on, but there is not a necessity to add a lot more to that sales base. And so you should see it sort of stabilize and then frankly it should be at a similar rate. Again, there will be fluctuations quarter in and quarter out, but it should move much over the course of the year. And that's really how you start to get the leverage as you move through the year and the top line really starts to show this momentum we have in the United States.

Our next question is from Josh Jennings with TD Cowen.

Juan José, congratulations on quite the ride, and it's great to hear that we'll continue with your continued active involvement with the company. I wanted to just ask, I know you're not providing details on the Femtech minimal invasive portfolio regulatory pathway, but was hoping you may just help us think about what steps are required prior to those pathways being fully developed in the US and China for Mia and for Preservé. If you can just help us think about what boxes need to be checked before that's finalized?

I think we've been trying to give as much color as possible in how we're going to bring the next generation of innovation into the US. And one of the things we've been saying is that really with the approval of the Motiva SmoothSilk Round and the Motiva SmoothSilk Ergonomix, it's already a different generation of implants from what you had available in the United States. Now one of the things we talked about today is the beginning of the process for the registration of tools necessary for Preservé. And I think that's very exciting, of course, given the excitement that breast tissue preservation is already having globally. If you look at what many of the surgeons even here in the United States are saying about breast tissue preservation, they're already very happy to put the implant above the muscle, saving the pectoralis muscle when and if possible, but there's a whole shift towards this movement we pioneered. So definitely having that process ongoing is going to help us with a potential launch of Preservé in the US. On top of that, you have the potential approval of the reconstruction indication for 2026. And remember, we recognize revenue at a much higher price when it comes to the reconstruction market, not only for Flora but eventually when approved for Motiva implants. Beyond that, there's the Ergonomix2 platform and that's what allows for, for me, which is basically those injectable implants that are done minimally invasive. So it really is about a super cycle of innovation. So you just think about how you're going to be seeing approvals and launches of innovative, real differentiated products in the US market in '26, '27 and '28. So we're not giving the exact dates, but I think you can be sure that you'll be seeing every year an important development in terms of innovation from us.

I wanted to follow up on the pipeline. Before the recent macro turmoil, your team had outlined a medium to long-term plan to reach $500 million in revenue. I understand this is not definitive, but could you share your level of confidence in achieving that target? Thank you.

I think in terms of that, in the second half of '23 and pretty much a big part of '24, what we saw is all of these macro pressures have an effect on aesthetics overall, both in the United States and also OUS. But I think aesthetics is really showing signs of resilience. We're already seeing good signs in APAC and EMEA. And Latin America, I think is the one lagging behind in that return to growth. But for us, with the US on board and all the dynamics that we are seeing and that rich innovation pipeline, I think it becomes, first of all, going back to the type of strong growth that this company had been doing prior to that period. So already this year, you're at 25% at the midpoint and with possibilities for doing even more. Beyond that, there's an important thing regarding our ability to get to that number eventually as a profitable company. And already this quarter, you see our gross margins at 68.5%. So it shows you how all the work that Pete has been doing in terms of rightsizing the company and all the efficiencies that we've been getting on top of selling our products at higher prices with higher revenue in the US and also into China. And as you go into those innovations, remember Preservé kind of like is in the midpoint between Motiva implants and EMEA. So that also should add a lot of good high-quality revenue for the company. So I think that's the difference, Josh, is that in the past we were just zeroed into getting to $500 million, and now we're like, well, we're going to get there as a profitable company.

Our next question is from Marie Thibault with BTIG.

Juan José just wanted to say good luck to you on your next phase. And Peter, it's nice to be working with you here going forward. I wanted to ask a question here about OUS revenue really. And when I think about this mid single-digit guide for OUS, it appears that's going to include that $8 million to $10 million in EMEA revenue. If I back that out, assuming of course you had some EMEA revenue in 2024, it looks like all you're needing to achieve is low single-digit growth OUS this year. Is that the right way to think about it? And if so, is there anything you can do to help us kind of think about the cadence throughout the year, things to think about in terms of seasonality, China distributor ordering, that sort of thing?

So a couple of things. We've been providing color all throughout the last year. The $8 million to $10 million we've given is the first time we have provided that number to give you some confidence that we're seeing stability. If you think about 2025, we do expect a gradual recovery in both EMEA and Asia Pacific this year; it's not as we expecting next year. The other important dynamic to consider in your outlook is that China for us, so 2024 was a year where we had sales into that market in China. That distributor has now set up their distribution network into China. We are not expecting much reordering in the first half of this year, but that will recover in the second half and we will start to see demand match kind of end market dynamics in China. We will see a little bit of currency headwinds in the first half of the year. But overall, you are correct. I mean, we should see growth over the course of the year gradually recover and we provided, I think, a pretty conservative start to the year in terms of what's needed to reach our numbers.

Conservative start to the year, that's good to hear. And then maybe my second question here on some of the EBITDA outlook you've given as well as the cash flow. Just want to quickly clarify, I think I heard for 2026 you're aiming for, I think I heard both cash flow breakeven or cash flow positive. Can you just clarify which one that is? And then should we think about the EBITDA trajectory throughout the year very similar to what you talked about for the cash burn trajectory in terms of a bit higher in Q1 and then improving meaningfully throughout the year?

So we've talked about achieving a quarter of EBITDA positive and getting to EBITDA positive here in 2025, and then a similar crossing the threshold to cash flow positive in 2026. In terms of your question about EBITDA and cash flow, it is similar, right? So as the year progresses, we expect the cash used and really EBITDA loss in the first quarter to be pretty similar to what it was in the fourth quarter. And again, reflecting that stepping up of the commercial efforts in the United States and the inventory needed to support those efforts. And then as the year goes on, you start to see the leverage, and we do, again, expect to achieve EBITDA positive in the second half of the year. And then you move into 2026, those dynamics continue and you cross over into cash flow positive.

Our next question is from Joanne Wuensch with Citibank.

It sounds like there's some good early momentum in the launch, and I'm curious what kind of physicians are adopting Motiva and what kind of patients are they targeting as the best patients for it? And I'll throw my second question out at the same time, which is, it sounds like you've started the year with about 40 active sales reps, but you're looking to expand it throughout 2025. How do you think about exiting 2025 in terms of sales reps?

I think it's really important to see that the US market has been starving for innovation for the last two decades. So of course, one of the things we are seeing is the excitement around the brand. Over 60 press articles, hundreds of social media posts from surgeons talking about having access to this amazing technology, having the ability to put this implant above the muscle safely, reducing device-related complications and all of it. We've had over 1.8 billion impressions in social media, and that has been organic. So when we see that what we have to do as a company is to make sure that women who were in the consideration phase for breast augmentation but had not made their decision based on safety or whether they were going to have an unnatural result, are receiving the type of messaging that they need to cross over and make it to their clinic, and that's something that is really important to see. We talked about the celebrity campaign that we have upcoming, and that's also going to make a difference because for the last two decades, aesthetic companies have not been really exclusively involved with the plastic surgeon, and we are. So what type of patients are they seeing? Patients who are excited about this technology, and those come from different age groups, but they're really going in there because of the innovation, the safety, and definitely when we look at the number of sales reps that we have today. We have what it takes. We will add probably selectively in big metro areas as the year progresses, but we have what it takes now.

Our next question is for Matt Taylor with Jefferies.

I wanted to start with one just on Motiva. And I was wondering what you're seeing here early, it's kind of related to the types of surgeons. But which incumbent do you think it's going to be easier to take share from in these end markets? Is there one that's easier than the other at this point?

In the United States, I think you've seen for market leader, AbbVie with Allergan Aesthetics, taking about 15% of the market and then Johnson & Johnson with Mentor in second place. And I think we're getting market share from everyone who believes in innovation in as a plastic surgeon. So they are the ones doing the first mover. But later on, we'll see people coming from all places. We're not selling our implants at a price point that attacks the low price market. So that's probably a place where we're not heading at this point. But definitely what we are seeing is that, for instance, when you look at Ergonomix, we were not expecting the share of Ergonomix in our total sales to be so high at this point. And Ergonomix is a more expensive product, truly differentiated from everything else that you see in the market. So those are the things that we'd like to see. Beyond that, I think over time we're going to be taking market share from everyone.

And can I ask a follow-up on Mia? I guess, I was just wondering your current thinking when you first introduced the concept years ago and had done market research, you talked about the potential for it to kind of double the TAM. And I know you've expressed in Europe, you're seeing kind of half those patients so far, so they weren't really in the market for augmentation until they saw this. So what do you think now in terms of what Mia could do for TAM expansion?

I think we remain very confident with that. I think it just happens over a longer period of time. The entire breast augmentation sector hasn't seen much growth in the last fifteen years. So having this real market expansion taking place over the next five to 10 years is going to make a big difference. And it happens at a high price point, by the way. So all of that is, of course, a positive. But again, Mia takes longer to develop. When you look at Preservé, think about like the 50% of patients that came in for Mia who, ultimately, aren't good Mia candidates. Then with Preservé and the potential launch of Preservé in different geographies, what we can do is provide to Mia interested patients who are not good candidates an option that is much superior and closer to what they were expecting. So I think the marriage of Mia and Preservé is a powerful one because not only are we working on the real market expansion piece, but also with Preservé, we're addressing the day-to-day needs of the plastic surgeon, and that's why it can be so impactful.

Our next question is from Mason Carrico with Stephens Inc.

This is Harrison on for Mason. I wanted to ask about what is baked in from US Motiva revenue here in 2025. Could you specify how many accounts and orders per day and sales reps you expect to end the year with?

So we have given the number of $35 million, right, which we expect to meet or exceed we've noted. In terms of the number of accounts and the pace of accounts, we're not going to provide that level of detail in our forecast. Again, given some of the metrics, Juan already described, we're seeing very strong growth. We're seeing very strong development in those numbers. Nothing we've seen thus far has given us any pause in endorsing that kind of outlook. In terms of sales reps, we've noted as well that the 40 reps we have in the field is the team we need. We can drive towards those numbers and more with that team. That will be selective as the year goes on if we see certain markets where we need to add a sales rep or divide territories and those types of things, we will do that to keep things healthy. But again, we don't need to do much more to achieve the numbers that we've described.

And then a quick follow-up here. I was wondering, or I just wanted to confirm, have you completely resolved all the supply challenges for Motiva, and was there any lingering impact we should expect in the first quarter?

As soon as we got the FDA approval, we've actually ramped up our capacity. We've added a third shift. So that enabled us to provide the amount of inventory that we needed for the launch in the US, and we don't expect to have any of those issues going into Q1 and beyond.

Thank you. There are no further questions at this time. I would like to hand the floor back over to Juan José Chacón-Quirós for any closing comments.

After 23 earnings calls, I did want to take the opportunity to thank all of the analysts who've been covering us for all these years and all the banks that have worked with us. I really see it as one of the great points of my career. I want to thank you for joining us on today's call. We will be at several conferences over the next few weeks, including CDs, MedTech and Life Sciences Access Day, and the Cowen Annual Healthcare Conference. We'll also have a large presence at the upcoming Aesthetic Society Meeting in Austin, Texas, and we look forward to seeing many of you at these events. We wish everyone continued good health and happiness.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.